GenomiCare

GenomiCare provides data-driven drug development services to biopharma and pharmaceutical companies.

[GenomiCare @GenomiCare]

Congratulations to GenomiCare’ Scientific Advisory Board member Dr. Chen Lieping， for being elected as new member of the National Academy of Sciences (NAS)。
https://t.co/ttNXqZYTa7
# NationalAcademyofSciences  #

[GenomiCare @GenomiCare]

GenomiCare Is on List of 2020 Deloitte China Technology Fast 50 & China Rising Star
https://t.co/FFe7mlyk2H

[GenomiCare @GenomiCare]

GenomiCare Wins Two Awards at 2020 International Sci-Tech Innovation Festival
GenomiCare is proud to announce that it has won the 2020 Leading Sci-Tech Innovation Company Award for its innovations in the R&D of cancer precision medicine.
https://t.co/iwRA3D5iUD

[GenomiCare @GenomiCare]

sharing how data-driven real-world clinical research solutions can provide biopharmaceutical companies with powerful data mining capabilities and assist in the development and commercialization of oncology drugs .

[GenomiCare @GenomiCare]

Dr. Xu Qiang, the founder, president and CEO of GenomiCare, attended the 2020 China BioMed Innovation and Investment Conference (CBIIC). At the meeting, he delivered a speech on "Data-driven algorithm accelerates new drug development",

[GenomiCare @GenomiCare]

aiming to speed up FDA/NMPA approvals by providing customized drug development strategies that help pharmaceuticals to better cope with unmet medical needs.

[GenomiCare @GenomiCare]

At the meeting, Dr. Xu Qiang demonstrated the extensive applications of the Clinical Intelligence Analysis Platform (CIAP) across the overall drug development course,

[GenomiCare @GenomiCare]

Dr. Xu Qiang, founder, president and CEO of Genomicare, was invited to report “ Data-driven algorithm accelerates new drug development " at 2020 DIA Digital Technology in Clinical Trials Conference"at 4 Sep, Nanjing.

[GenomiCare @GenomiCare]

can support cancer translational research and tumor drug clinical development, by illustrating an example of the application of CIAP and data driven algorithm in the real world data setting.

[GenomiCare @GenomiCare]

In his speech, Dr. Xu Qiang emphasized how real-world oncology clinical-genomic data combined with GenomiCare’s proprietary artificial intelligence data-driven algorithm and Clinical Intelligence Analysis Platform (CIAP)

[GenomiCare @GenomiCare]

Dr. Xu Qiang, founder, president and CEO of Genomicare, will give an oral report named "Data-driven algorithm accelerates new drug development”at the "Cancer Diagnosis and Treatment Black Technology Conference" on September 2nd.

[NEJM @NEJM]

Patients with chronic coronary disease were randomized to daily colchicine or placebo. Incidence of the composite endpoint of cardiovascular death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization was significantly lower with colchicine. #ESCCongress

[GenomiCare @GenomiCare]

Dr. Xu Qiang, founder, president and CEO of Genomicare, was invited to report “ Data-driven algorithm accelerates new drug development " at 2020 DIA Digital Technology in Clinical Trials Conference"at 4 Sep, Nanjing.

[GenomiCare @GenomiCare]

GenomiCare and Laekna Therapeutics today announced an expanded strategic collaboration, focusing on indications expansion and combination therapy for cancer patients.

[GenomiCare @GenomiCare]

Dr. Xu Qiang, founder, president and CEO of Genomicare, will give an oral report named "Data-driven algorithm accelerates new drug development”at the "Cancer Diagnosis and Treatment Black Technology Conference" on September 2nd.

[GenomiCare @GenomiCare]

GenomiCare Partners with AWS on HIPAA Eligible Services for Higher Data Security https://t.co/H5OeYOMW5X